Clinical trial · Interventional
Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): 1st years Enrollment #s showed study was not going to meet criteria randomization.
Summary
Brief summary (as posted)
This is a comparison, at this VA Hospital,of routine multi-visit and multi-testing for solid tumor recurrence in four tumor groups to a limited scheduled 5 visit history/physical with PET/CT only, over a five year period. The purpose is to show through utilization of the single most sensitive and specific test currently available-PET/CT-that survival for patients in follow-up can be improved.(Plus lowering medical costs and increasing patient confidence and compliance with follow-up appointments).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Recurrence | — | UNRESOLVED | — |
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NCCN recommendations for solid tumor post treatment | Procedure | — | UNRESOLVED |
| PET/CT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- PET/CT follow-up
- description
- PET/CT with history and physical exams at 3,9,18,36,60 months only
- interventionNames
- Procedure: PET/CT
- type
- OTHER
- label
- conventional follow-up
- description
- NCCN recommendations
- interventionNames
- Procedure: NCCN recommendations for solid tumor post treatment
Primary outcomes (1)
- measure
- ThatPET/CT will be superior (15% improvement) to conventional methods of follow-up in terms of 5 year survival, cost and time to identification of new disease
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Completed primary therapy such that no disease is evident at the time of enrollment in the study Exclusion Criteria: * Patients unable to consent * Without diagnosis of colorectal cancer * Non-small cell lung cancer or squamous cell cancer of the head and neck * Unwilling or unable to participate in the assigned follow-up program * Having a serum glucose at time of PET/CT greater than 180mg/dl * Stage IV disease or with evidence of disease recurrence post treatment * Who are not a candidate for further treatment should a recurrence of disease be identified
References
Publications (0)
Data not yet available